Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Feasibility and Safety of Whole Heart Radiotherapy for End-stage Heart Failure: First In-human Treatments

NCT06299176 is registered in ClinicalTrials.gov with McGill University Health Centre/Research Institute of the McGill University Health Centre as lead sponsor.

NCT NCT06299176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06299176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Feasibility and Safety of Whole Heart Radiotherapy for End-stage Heart Failure: First In-human Treatments
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
April 30, 2025
Completion date
December 31, 2026
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage heart failure, heart failure nyha class iii, heart failure nyha class iv, heart failure with reduced ejection fraction